Oppenheimer analyst Leland Gershell upgrades Avalo Therapeutics (NASDAQ:AVTX) from Perform to Outperform and announces $35 price target.
Oppenheimer Upgrades Avalo Therapeutics to Outperform, Announces $35 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.